Filed with ASX · · 5 pages · English
Noxopharm Ltd. has announced a successful equity raising of funds through a placement to advance its clinical program for SOF-SKN. The company has received commitments for a significant amount from professional and sophisticated investors, along with plans for a share purchase plan for eligible shareholders. Proceeds from this equity raising will support various clinical and research activities, including an extension study for patients with cutaneous lupus erythematosus.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Noxopharm undertakes Equity Raising to advance SOF-SKN™ clinical program Highlights • Commitments received for a $1.5 million Placement of New Shares (Placement) to domestic professional and sophisticated investors • $1.0 million Share Purchase Plan (SPP) to be made available to eligible...
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm